| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
80 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-236 |
| Cash Flow (TTM) (Millions $) |
25 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
The Medicines Co is a biopharmaceutical company that specializes in the development and commercialization of innovative, acute care cardiovascular therapeutics. They focus on creating products that address unmet medical needs and have the potential to significantly improve patient outcomes.
The company is known for its expertise in the area of antithrombotic therapies, particularly in patients undergoing percutaneous coronary intervention (PCI) procedures. Their flagship product is Angiomax (bivalirudin), an intravenous direct thrombin inhibitor used as an anticoagulant during PCI procedures.
In addition to Angiomax, the Medicines Co has a diverse pipeline of investigational products targeting various cardiovascular diseases and conditions, such as acute coronary syndrome, acute decompensated heart failure, and high-risk atherosclerosis. They prioritize drugs that can be administered in hospital settings and provide immediate and effective treatment.
The Medicines Co is committed to bringing innovative therapies to patients in need and has a strong focus on clinical research and development. They collaborate with academic institutions, healthcare professionals, and industry partners to advance their pipeline and ensure the safety and efficacy of their products.
Overall, the Medicines Co aims to transform the treatment landscape for acute cardiovascular diseases by delivering breakthrough therapies that improve patient outcomes and reduce the burden of these conditions on individuals and healthcare systems.
Company Address: 8 Sylvan Way Parsippany 7054 NJ
Company Phone Number: 290-6000 Stock Exchange / Ticker: NASDAQ MDCO
|
%
1.75%